Note to Instructors: Sparrow Therapeutics Exit Strategy
The case focuses on Ken Powers, co-founder and CEO of Sparrow Therapeutics, whose young biotechnology company has reached a critical stage where he has to decide whether or not to sell. The company’s three main sets of investors have different priorities: (1) a quick cash sale now (2) delay sale for about a year if returns are greater and (3) delay sale for two years, build company value and retain autonomy. What choice would be best for the company, for its investors and – and for Ken himself? And when would be the best time to implement the exit strategy?